
March 17, 2023
In this episode of the Rising Tide series for frontline professionals, the patients themselves and caregivers, co-hosts Ken Cusi and Roger Green are joined by KOL in hepatology, Manal Abdelmalek and KOL in endocrinology, Scott Isaacs for a deeper dive into Fatty Liver, NAFLD and NASH. The group discusses: morbidities and mortalities related to fatty liver disease, paradigm-shifting data, screening for risk stratification, pediatric and adolescent populations, unique key takeaways and much more.
Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.
Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.
The Surfers evaluate a draft report from the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. This high-caliber session offers a plethora of practical considerations around accessing approved NASH pharmacotherapies for those most in need.
Learn about the amazingly diverse and exciting program for Day Two of the inaugural Innovations in NAFLD Care 2022 Workshop, with sessions on Comprehensive Care pathways, current and future pharmacotherapies, and what a future integrated treatment roadmap might look like.
The podcast ventures into the emergence of digital therapeutics with Joe Rubinsztain, CEO and Co-Founder of ChronWell, and Mark Berman, CMO of Better Therapeutics. In this final conversation, the panelists provide closing thoughts on the future of this space and how it may play out across different economic systems.
The podcast ventures into the emerging space of digital therapeutics with Joe Rubinsztain, CEO and Co-Founder of ChronWell, and Mark Berman, CMO of Better Therapeutics. The panelists consider regulatory challenges for prescribing digital therapeutics as an evidence-based treatment. Additionally, Louise Campbell introduces a free lifestyle app that she is working on that aims to improve liver health.
Joe Rubinsztain, CEO and Co-Founder of ChronWell, discusses scalable technology and the future of digital health. Within this context, the panelists consider the dynamics of insurers, providers and building an understanding around the full spectrum of disease treatment.
Naim Alkhouri shares his experience conducting a feasibility study with Better Therapeutics aimed at improving liver health through use of an app. The panelists discuss cognitive behavioral therapy, noninvasive technologies, assessing endpoints and much more.
The podcast ventures into the emerging digital therapeutics space with Joe Rubinsztain, CEO and Co-Founder of ChronWell, and Mark Berman, CMO of Better Therapeutics. In this conversation, both guests share their unique backgrounds and paths to combating Fatty Liver through technological innovation.